Krief Patricia, Maytal Joseph
Division of Pediatric Neurology, North Shore Long Island Jewish Medical Center, Schneider Children's Hospital, Albert Einstein College of Medicine, New Hyde Park, NY 11040, USA.
J Child Neurol. 2008 May;23(5):582-4. doi: 10.1177/0883073807309781.
Despite the high incidence of epilepsy in very young children, the availability of approved antiepileptic drugs for this population is limited. This study assessed the efficacy and tolerability of levetiracetam in children younger than 2 years of age with various types of epilepsy. A single-center, retrospective chart review of 28 patients ranging in age from 2 weeks to 22 months treated with levetiracetam over a 2.5-year period was conducted. The mean dosage of levetiracetam was 39 mg/kg per day, and the mean duration of treatment was 6.3 months. The majority of patients (54%) were also taking 1 or 2 other antiepileptic drugs. A reduction in seizure frequency was found in 54%, with 14% achieving seizure freedom. Eight patients showed no response to levetiracetam treatment. Efficacy was highest among patients with generalized epilepsy. Adverse effects occurred in 2 patients and were behavioral in nature. Levetiracetam treatment was safe and effective in this group of very young patients with various types of epilepsy.
尽管幼儿癫痫发病率很高,但适用于该人群的获批抗癫痫药物却很有限。本研究评估了左乙拉西坦对2岁以下各类癫痫患儿的疗效和耐受性。对28例年龄在2周龄至22月龄之间、在2.5年期间接受左乙拉西坦治疗的患儿进行了一项单中心回顾性病历审查。左乙拉西坦的平均剂量为每日39mg/kg,平均治疗时长为6.3个月。大多数患者(54%)同时还服用1种或2种其他抗癫痫药物。54%的患者癫痫发作频率降低,其中14%实现无癫痫发作。8例患者对左乙拉西坦治疗无反应。在全身性癫痫患者中疗效最高。2例患者出现不良反应,均为行为方面的不良反应。左乙拉西坦治疗对这组患有各类癫痫的极幼龄患者安全有效。